[go: up one dir, main page]

MX349551B - Proceso para preparar compuestos tienopirimidinas. - Google Patents

Proceso para preparar compuestos tienopirimidinas.

Info

Publication number
MX349551B
MX349551B MX2015004467A MX2015004467A MX349551B MX 349551 B MX349551 B MX 349551B MX 2015004467 A MX2015004467 A MX 2015004467A MX 2015004467 A MX2015004467 A MX 2015004467A MX 349551 B MX349551 B MX 349551B
Authority
MX
Mexico
Prior art keywords
making
thienopyrimidine compounds
methyl
thienopyrimidine
compounds
Prior art date
Application number
MX2015004467A
Other languages
English (en)
Other versions
MX2015004467A (es
Inventor
Babu Srinivasan
Cheng Zhigang
Gosselin Francis
Hidber Pirmin
Hoffmann Ursula
Humphries Theresa
Reents Reinhard
Tian Qingping
Yajima Herbert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015004467A publication Critical patent/MX2015004467A/es
Publication of MX349551B publication Critical patent/MX349551B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Métodos de procedimiento para preparar el inhibidor dual de Mtor/PI3K GDC-0980, denominado (S)-1-(4-((2-(2-aminopirimidín-5-il )-7-metil-4-morfolinotieno[3,2-d]pirimidín-6-il)metil)piperazín-1 -il)-2-hidroxipropán-1-ona, que presenta la estructura: y estereoisómeros, isómeros geométricos, tautómeros y sales farmacéuticamente aceptables de los mismos.
MX2015004467A 2012-10-10 2013-10-09 Proceso para preparar compuestos tienopirimidinas. MX349551B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261711900P 2012-10-10 2012-10-10
PCT/EP2013/070994 WO2014056955A1 (en) 2012-10-10 2013-10-09 Process for making thienopyrimidine compounds

Publications (2)

Publication Number Publication Date
MX2015004467A MX2015004467A (es) 2015-07-14
MX349551B true MX349551B (es) 2017-08-02

Family

ID=49322377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004467A MX349551B (es) 2012-10-10 2013-10-09 Proceso para preparar compuestos tienopirimidinas.

Country Status (13)

Country Link
US (1) US8895729B2 (es)
EP (1) EP2906566B1 (es)
JP (1) JP6123097B2 (es)
KR (1) KR101698283B1 (es)
CN (2) CN104718212B (es)
AR (1) AR092960A1 (es)
BR (1) BR112015007970A8 (es)
CA (1) CA2883513A1 (es)
ES (1) ES2594078T3 (es)
HK (2) HK1211026A1 (es)
MX (1) MX349551B (es)
RU (1) RU2637309C2 (es)
WO (1) WO2014056955A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349551B (es) * 2012-10-10 2017-08-02 Hoffmann La Roche Proceso para preparar compuestos tienopirimidinas.
WO2014180752A1 (en) 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Process for the preparation of boronic acid intermediates
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AU2017355385A1 (en) * 2016-11-02 2019-05-30 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
CN113717049A (zh) * 2021-08-05 2021-11-30 江西兄弟医药有限公司 一种制备（s）-乙酰氧基丙酰氯的半连续方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ES2579402T3 (es) 2001-07-12 2016-08-11 Reaxa Limited Catalizador microencapsulado, métodos de preparación y métodos de uso de este
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2041139B1 (en) 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
GB0608264D0 (en) * 2006-04-26 2006-06-07 Piramed Ltd Pharmaceutical compounds
BRPI0717923A2 (pt) 2006-12-07 2013-10-22 Genentech In '' composto, composição farmacêutica, método para tratar um câncer, processo para a produção de uma composição farmacêutica, usos, métodos para inibir ou modular a atividade da lipídeo quinase e kit ' '
ZA200904534B (en) * 2006-12-07 2010-09-29 Hoffmann La Roche Phosphoinositide 3-kinase inhibitor compounds and methods of use
AR064154A1 (es) 2006-12-07 2009-03-18 Piramed Ltd Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
ES2537352T3 (es) 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009076622A2 (en) 2007-12-12 2009-06-18 Massachusetts Institute Of Technology Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof
JP5709766B2 (ja) * 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
CA2835760A1 (en) 2011-06-03 2012-12-06 F. Hoffmann-La Roche Ag Methods of treating mesothelioma with a pi3k inhibitor compound
CN102399235A (zh) * 2011-10-25 2012-04-04 江苏弘和药物研发有限公司 一种2-氨基-5-嘧啶硼酸频哪醇酯的合成方法
CN102367260A (zh) * 2011-12-12 2012-03-07 南京药石药物研发有限公司 2-氨基嘧啶-5-硼酸的合成方法
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
MX349551B (es) * 2012-10-10 2017-08-02 Hoffmann La Roche Proceso para preparar compuestos tienopirimidinas.
CN102993163A (zh) * 2012-12-07 2013-03-27 青岛前线生物工程有限公司 3-甲基噻吩-2-甲醛的合成方法

Also Published As

Publication number Publication date
HK1211026A1 (en) 2016-05-13
ES2594078T3 (es) 2016-12-15
KR101698283B1 (ko) 2017-01-19
JP2015534572A (ja) 2015-12-03
US8895729B2 (en) 2014-11-25
CN107188898B (zh) 2019-12-03
BR112015007970A8 (pt) 2019-08-27
CN104718212A (zh) 2015-06-17
RU2637309C2 (ru) 2017-12-04
JP6123097B2 (ja) 2017-05-10
CN107188898A (zh) 2017-09-22
KR20150054945A (ko) 2015-05-20
HK1244272A1 (zh) 2018-08-03
EP2906566A1 (en) 2015-08-19
AR092960A1 (es) 2015-05-06
CA2883513A1 (en) 2014-04-17
BR112015007970A2 (pt) 2017-07-04
CN104718212B (zh) 2017-06-16
US20140100366A1 (en) 2014-04-10
WO2014056955A1 (en) 2014-04-17
EP2906566B1 (en) 2016-08-24
MX2015004467A (es) 2015-07-14
RU2015113747A (ru) 2016-12-10

Similar Documents

Publication Publication Date Title
MX349551B (es) Proceso para preparar compuestos tienopirimidinas.
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
CR20140332A (es) Inhibidores de bromodominios
MX348470B (es) Pirimidinas anilladas sustituidas y uso de las mismas.
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12015500813B1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
NZ608031A (en) Inhibitors of notum pectinacetylesterase and methods of their use
GEP20156423B (en) 9-[4-(3-chlor-2-fluorphenylamino)-7-methoxy- quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, usage thereas drug, and production thereof
MX2014002473A (es) Compuestos (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1 / antagonistas 5 -ht2a de actividad doble.
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
MX2017008430A (es) Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.
MX356804B (es) Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos.
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles

Legal Events

Date Code Title Description
FG Grant or registration